This company seems to have been delisted
Reason: Voluntary Delisting
Last recorded trade on: July 19, 2024
Source: https://www.businesswire.com/news/home/20240430653360/en/Merrimack-Pharmaceuticals-Announces-Notification-of-Plan-to-Voluntary-Delist-Common-Stock-on-NASDAQ-Subject-to-Receipt-of-Stockholder-Approval-of-Plan-of-Dissolution
Reason: Voluntary Delisting
Last recorded trade on: July 19, 2024
Source: https://www.businesswire.com/news/home/20240430653360/en/Merrimack-Pharmaceuticals-Announces-Notification-of-Plan-to-Voluntary-Delist-Common-Stock-on-NASDAQ-Subject-to-Receipt-of-Stockholder-Approval-of-Plan-of-Dissolution
Merrimack Pharmaceuticals
MACK
C$20.71
Share price
0.00%
Change (1 day)
3.20%
Change (1 year)
Categories
Merrimack Pharmaceuticals (MACK) - Total debt
Total debt on the balance sheet as of March 2019 : C$22.72 Million
According to Merrimack Pharmaceuticals's latest financial reports the company's total debt is C$22.72 Million. A company’s total debt is the sum of all current and non-current debts.
Merrimack Pharmaceuticals - Total debt on balance sheet (from 2010 to 2019)
Total debt by year
| Year | Total debt | Change |
|---|---|---|
| 2018-12-31 | C$20.26 M | |
| 2017-12-31 | N/A | -100% |
| 2016-12-31 | C$0.29 B | -18.46% |
| 2015-12-31 | C$0.35 B | 156.66% |
| 2014-12-31 | C$0.13 B | 17.15% |
| 2013-12-31 | C$0.11 B | 199.96% |
| 2012-12-31 | C$39.63 M | 81070.15% |
| 2011-12-31 | C$0.04 M | -90.05% |
| 2010-12-31 | C$0.49 M | -65.58% |
| 2009-12-31 | C$1.42 M |
Total debt for similar companies or competitors
| Company | Total debt/th> | differencediff. | Country |
|---|---|---|---|
 Sanofi SNY | C$31.16 B | 137,079.95% | 🇫🇷 France |
 AVEO Oncology
AVEO | C$52.94 M | 133.03% | 🇺🇸 USA |
 Geron GERN | C$0.16 B | 633.65% | 🇺🇸 USA |
 Clovis Oncology CLVS | C$0.93 B | 4,000.37% | 🇺🇸 USA |
 Eterna Therapeutics ERNA | C$3.94 M | -82.64% | 🇺🇸 USA |